Hypochondroplasia Clinical Trial
Official title:
Prospective Clinical Assessment Study in Children With Hypochondroplasia: ACCEL
This is a long-term, multicenter, non-interventional study of children ages 2.5 to <17 years with hypochondroplasia (HCH).
The objective is to evaluate growth, HCH-related medical complications, health-related quality of life, functional abilities and cognitive functions of study participants. Data collected will contribute to the characterization of the natural history of children with HCH. No study medication will be administered. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05328050 -
Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
|
||
| Recruiting |
NCT06212947 -
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
|
||
| Completed |
NCT01111019 -
Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children
|
Phase 2 | |
| Completed |
NCT01541306 -
C-Type Natriuretic Peptide and Achondroplasia
|
N/A |